Literature DB >> 21046361

In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity.

Anna Vávrová1, Olga Popelová, Martin Stěrba, Eduard Jirkovský, Pavlína Hašková, Helena Mertlíková-Kaiserová, Vladimír Geršl, Tomáš Simůnek.   

Abstract

The clinical usefulness of anthracycline antineoplastic drugs is limited by their cardiotoxicity. Its mechanisms have not been fully understood, although the induction of oxidative stress is widely believed to play the principal role. Glutathione is the dominant cellular antioxidant, while glutathione peroxidase (GPx) together with glutathione reductase (GR) constitutes the major enzymatic system protecting the cardiac cells from oxidative damage. Therefore, this study aimed to assess their roles in anthracycline cardiotoxicity. Ten-week intravenous administration of daunorubicin (DAU, 3 mg/kg weekly) to rabbits induced heart failure, which was evident from decreased left ventricular ejection fraction and release of cardiac troponins to circulation. However, no significant changes in either total or oxidized glutathione contents or GR activity were detected in left ventricular tissue of DAU-treated rabbits when compared with control animals. GPx activity in the cardiac tissue significantly increased. In H9c2 rat cardiac cells, 24-h DAU exposure (0.1-10 μM) induced significant dose-dependent toxicity. Cellular content of reduced glutathione was insignificantly decreased, oxidized glutathione and GR activity were unaffected, and GPx activity was significantly increased. Neither buthionine sulfoximine (BSO, glutathione biosynthesis inhibitor) nor 2-oxo-4-thiazolidine-carboxylic acid (OTC, glutathione biosynthetic precursor) had significant effects on DAU cytotoxicity. This contrasted with model oxidative injury induced by hydrogen peroxide, which cytotoxicity was increased by BSO and decreased by OTC. In conclusion, our results suggest that the dysfunction of glutathione antioxidant system does not play a causative role in anthracycline cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21046361     DOI: 10.1007/s00204-010-0615-8

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  9 in total

Review 1.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

2.  Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Authors:  Anna Vavrova; Hana Jansova; Eliska Mackova; Miloslav Machacek; Pavlina Haskova; Lucie Tichotova; Martin Sterba; Tomas Simunek
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

3.  An Upgrade on the Rabbit Model of Anthracycline-Induced Cardiomyopathy: Shorter Protocol, Reduced Mortality, and Higher Incidence of Overt Dilated Cardiomyopathy.

Authors:  Jesús Talavera; Alejandro Giraldo; María Josefa Fernández-Del-Palacio; Obdulio García-Nicolás; Juan Seva; Gavin Brooks; Jose M Moraleda
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

4.  Key messages of recent publications in the field of toxicology.

Authors:  C Cadenas; R Marchan; P Godoy; R Reif; I von Recklinghausen; N Schöbel
Journal:  EXCLI J       Date:  2012-11-09       Impact factor: 4.068

5.  Vitamin A supplementation modifies the antioxidant system in rats.

Authors:  Jung-Hwa Cha; Qi-Ming Yu; Jung-Sook Seo
Journal:  Nutr Res Pract       Date:  2015-12-11       Impact factor: 1.926

Review 6.  The role of Nrf2-mediated pathway in cardiac remodeling and heart failure.

Authors:  Shanshan Zhou; Wanqing Sun; Zhiguo Zhang; Yang Zheng
Journal:  Oxid Med Cell Longev       Date:  2014-07-01       Impact factor: 6.543

7.  In vitro test systems and their limitations.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2013-12-12       Impact factor: 4.068

8.  Cardiotoxicity of anthracycline therapy: current perspectives.

Authors:  Mihaela Valcovici; Florina Andrica; Corina Serban; Simona Dragan
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

Review 9.  A Review on the Effect of Traditional Chinese Medicine Against Anthracycline-Induced Cardiac Toxicity.

Authors:  Xinyu Yang; Nian Liu; Xinye Li; Yihan Yang; Xiaofeng Wang; Linling Li; Le Jiang; Yonghong Gao; Hebin Tang; Yong Tang; Yanwei Xing; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.